• 1
    Parkin DM, Bray F, Ferlay J, Pisani P. Global cancer statistics, 2002. CA Cancer J Clin 2005; 55: 74108.
  • 2
    Poon RT, Fan ST. Hepatectomy for hepatocellular carcinoma: patient selection and postoperative outcome. Liver Transpl 2004; 10(Suppl): S39S45.
  • 3
    El-Serag HB, Marrero JA, Rudolph L, Reddy KR. Diagnosis and treatment of hepatocellular carcinoma. Gastroenterology 2008; 134: 17521763.
  • 4
    Zender L, Xue W, Zuber J, Semighini CP, Krasnitz A, Ma B, et al. An oncogenomics-based in vivo RNAi screen identifies tumor suppressors in liver cancer. Cell 2008; 135: 852864.
  • 5
    Lee NP, Leung KW, Cheung N, Lam BY, Xu MZ, Sham PC, et al. Comparative proteomic analysis of mouse livers from embryo to adult reveals an association with progression of hepatocellular carcinoma. Proteomics 2008; 8: 21362149.
  • 6
    Zender L, Spector MS, Xue W, Flemming P, Cordon-Cardo C, Silke J, et al. Identification and validation of oncogenes in liver cancer using an integrative oncogenomic approach. Cell 2006; 125: 12531267.
  • 7
    Wong BW, Luk JM, Ng IO, Hu MY, Liu KD, Fan ST. Identification of liver-intestine cadherin in hepatocellular carcinoma—a potential disease marker. Biochem Biophys Res Commun 2003; 311: 618624.
  • 8
    Wendeler MW, Jung R, Himmelbauer H, Gessner R. Unique gene structure and paralogy define the 7D-cadherin family. Cell Mol Life Sci 2006; 63: 15641573.
  • 9
    Grotzinger C, Kneifel J, Patschan D, Schnoy N, Anagnostopoulos I, Faiss S, et al. LI-cadherin: a marker of gastric metaplasia and neoplasia. Gut 2001; 49: 7381.
  • 10
    Takamura M, Sakamoto M, Ino Y, Shimamura T, Ichida T, Asakura H, et al. Expression of liver-intestine cadherin and its possible interaction with galectin-3 in ductal adenocarcinoma of the pancreas. Cancer Sci 2003; 94: 425430.
  • 11
    Wang XQ, Luk JM, Leung PP, Wong BW, Stanbridge EJ, Fan ST. Alternative mRNA splicing of liver intestine-cadherin in hepatocellular carcinoma. Clin Cancer Res 2005; 11: 483489.
  • 12
    Takamura M, Ichida T, Matsuda Y, Kobayashi M, Yamagiwa S, Genda T, et al. Reduced expression of liver-intestine cadherin is associated with progression and lymph node metastasis of human colorectal carcinoma. Cancer Lett 2004; 212: 253259.
  • 13
    Berndorff D, Gessner R, Kreft B, Schnoy N, Lajous-Petter AM, Loch N, et al. Liver-intestine cadherin: molecular cloning and characterization of a novel Ca2+-dependent cell adhesion molecule expressed in liver and intestine. J Cell Biol 1994; 125: 13531369.
  • 14
    Dantzig AH, Hoskins JA, Tabas LB, Bright S, Shepard RL, Jenkins IL, et al. Association of intestinal peptide transport with a protein related to the cadherin superfamily. Science 1994; 264: 430433.
  • 15
    Park SS, Kang SH, Park JM, Kim JH, Oh SC, Lee JH, et al. Expression of liver-intestine cadherin and its correlation with lymph node metastasis in gastric cancer: can it predict N stage preoperatively? Ann Surg Oncol 2007; 14: 9499.
  • 16
    Ko S, Chu KM, Luk JM, Wong BW, Yuen ST, Leung SY, et al. Overexpression of LI-cadherin in gastric cancer is associated with lymph node metastasis. Biochem Biophys Res Commun 2004; 319: 562568.
  • 17
    Wang XQ, Luk JM, Garcia-Barcelo M, Miao X, Leung PP, Ho DW, et al. Liver intestine-cadherin (CDH17) haplotype is associated with increased risk of hepatocellular carcinoma. Clin Cancer Res 2006; 12: 52485252.
  • 18
    Hu L, Wen JM, Sham JS, Wang W, Xie D, Tjia WM, et al. Establishment of cell lines from a primary hepatocellular carcinoma and its metastatis. Cancer Genet Cytogenet 2004; 148: 8084.
  • 19
    Li Y, Tang ZY, Ye SL, Liu YK, Chen J, Xue Q, et al. Establishment of cell clones with different metastatic potential from the metastatic hepatocellular carcinoma cell line MHCC97. World J Gastroenterol 2001; 7: 630636.
  • 20
    Brown JJ, Parashar B, Moshage H, Tanaka KE, Engelhardt D, Rabbani E, et al. A long-term hepatitis B viremia model generated by transplanting nontumorigenic immortalized human hepatocytes in Rag-2-deficient mice. HEPATOLOGY 2000; 31: 173181.
  • 21
    Luk MC, Tsang RS, Ng MH. Murine monoclonal antibody specific for lipopolysaccharide of Salmonella serogroup A. J Clin Microbiol 1987; 25: 21402144.
  • 22
    Chen Y, Lin MC, Yao H, Wang H, Zhang AQ, Yu J, et al. Lentivirus-mediated RNA interference targeting enhancer of zeste homolog 2 inhibits hepatocellular carcinoma growth through down-regulation of stathmin. HEPATOLOGY 2007; 46: 200208.
  • 23
    Lee NP, Leung KW, Wo JY, Tam PC, Yeung WS, Luk JM. Blockage of testicular connexins induced apoptosis in rat seminiferous epithelium. Apoptosis 2006; 11: 12151229.
  • 24
    Shah SP, Lam WL, Ng RT, Murphy KP. Modeling recurrent DNA copy number alterations in array CGH data. Bioinformatics 2007; 23: i450i458.
  • 25
    Zender L, Xue W, Cordon-Cardo C, Hannon GJ, Lucito R, Powers S, et al. Generation and analysis of genetically defined liver carcinomas derived from bipotential liver progenitors. Cold Spring Harb Symp Quant Biol 2005; 70: 251261.
  • 26
    Kaposi-Novak P, Lee JS, Gomez-Quiroz L, Coulouarn C, Factor VM, Thorgeirsson SS. Met-regulated expression signature defines a subset of human hepatocellular carcinomas with poor prognosis and aggressive phenotype. J Clin Invest 2006; 116: 15821595.
  • 27
    Kwak JM, Min BW, Lee JH, Choi JS, Lee SI, Park SS, et al. The prognostic significance of E-cadherin and liver intestine-cadherin expression in colorectal cancer. Dis Colon Rectum 2007; 50: 18731880.
  • 28
    Ge J, Chen Z, Wu S, Yuan W, Hu B. A clinicopathological study on the expression of cadherin-17 and caudal-related homeobox transcription factor (CDX2) in human gastric carcinoma. Clin Oncol (R Coll Radiol) 2008; 20: 275283.
  • 29
    Ito R, Oue N, Yoshida K, Kunimitsu K, Nakayama H, Nakachi K, et al. Clinicopathological significant and prognostic influence of cadherin-17 expression in gastric cancer. Virchows Arch 2005; 447: 717722.
  • 30
    Dey A, Verma CS, Lane DP. Updates on p53: modulation of p53 degradation as a therapeutic approach. Br J Cancer 2008; 98: 48.
  • 31
    Wang W, El-Deiry WS. Restoration of p53 to limit tumor growth. Curr Opin Oncol 2008; 20: 9096.
  • 32
    Pineau P, Marchio A, Battiston C, Cordina E, Russo A, Terris B, et al. Chromosome instability in human hepatocellular carcinoma depends on p53 status and aflatoxin exposure. Mutat Res 2008; 653: 613.
  • 33
    Edamoto Y, Hara A, Biernat W, Terracciano L, Cathomas G, Riehle HM, et al. Alterations of RB1, p53 and Wnt pathways in hepatocellular carcinomas associated with hepatitis C, hepatitis B and alcoholic liver cirrhosis. Int J Cancer 2003; 106: 334341.
  • 34
    Goessling W, North TE, Loewer S, Lord AM, Lee S, Stoick-Cooper CL, et al. Genetic interaction of PGE2 and Wnt signaling regulates developmental specification of stem cells and regeneration. Cell 2009; 136: 11361147.
  • 35
    Baumgartner W, Wendeler MW, Weth A, Koob R, Drenckhahn D, Gessner R. Heterotypic trans-interaction of LI- and E-cadherin and their localization in plasmalemmal microdomains. J Mol Biol 2008; 378: 4454.
  • 36
    Wendeler MW, Drenckhahn D, Gessner R, Baumgartner W. Intestinal LI-cadherin acts as a Ca2+-dependent adhesion switch. J Mol Biol 2007; 370: 220230.